litlas
ログインアカウント作成

Thomas W. Flaig

2006–2025 年に発表

69
論文数
20,739
被引用数
41
h 指数
66
i10 指数

被引用数

Thomas W. Flaig の年別被引用数1994 年: 被引用 3 件2000 年: 被引用 1 件2001 年: 被引用 1 件2006 年: 被引用 1 件2007 年: 被引用 9 件2008 年: 被引用 5 件2009 年: 被引用 11 件2010 年: 被引用 11 件2011 年: 被引用 37 件2012 年: 被引用 75 件2013 年: 被引用 219 件2014 年: 被引用 238 件2015 年: 被引用 242 件2016 年: 被引用 237 件2017 年: 被引用 219 件2018 年: 被引用 243 件2019 年: 被引用 744 件2020 年: 被引用 763 件2021 年: 被引用 825 件2022 年: 被引用 569 件2023 年: 被引用 481 件2024 年: 被引用 878 件2025 年: 被引用 356 件2026 年: 被引用 16 件1995〜1999 年は被引用が無いため表示していません2002〜2005 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,003 件、この内訳の 25.4%中国: 引用元論文 653 件、この内訳の 8.3%イギリス: 引用元論文 533 件、この内訳の 6.8%イタリア: 引用元論文 482 件、この内訳の 6.1%カナダ: 引用元論文 439 件、この内訳の 5.6%ドイツ: 引用元論文 392 件、この内訳の 5%フランス: 引用元論文 360 件、この内訳の 4.6%スペイン: 引用元論文 262 件、この内訳の 3.3%日本: 引用元論文 249 件、この内訳の 3.2%オランダ: 引用元論文 215 件、この内訳の 2.7%オーストラリア: 引用元論文 208 件、この内訳の 2.6%ベルギー: 引用元論文 170 件、この内訳の 2.2%
0%25.4%その他 24.2%

機関

分野

  • Medicine79.3%
  • Biochemistry, Genetics and Molecular Biology14.3%
  • Immunology and Microbiology2.7%
  • Computer Science0.7%
  • Pharmacology, Toxicology and Pharmaceutics0.6%
  • Engineering0.4%
  • その他2%

トピック

  • Prostate Cancer Treatment and Research15.9%
  • Prostate Cancer Diagnosis and Treatment7.2%
  • Bladder and Urothelial Cancer Treatments7.1%
  • Cancer Immunotherapy and Biomarkers4.1%
  • Radiopharmaceutical Chemistry and Applications3.9%
  • Urinary and Genital Oncology Studies3.8%
  • その他58%

共著者

全論文

検索で開く
  1. Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

    著者: Howard I. Scher, Karim Fizazi, Fred Saad, Mary‐Ellen Taplin, Cora N. Sternberg, Kurt Miller, Ronald de Wit, Peter F.A. Mulders, Kim N., Neal D. Shore, Andrew J. Armstrong, Thomas W. Flaig, Aude Fléchon, Paul N. Mainwaring, Mark T. Fleming, John D. Hainsworth, Mohammad Hirmand, Bryan Selby, Lynn Seely, Johann S. de Bono - New England Journal of Medicine 2012 被引用: 4,574

  2. Abiraterone and Increased Survival in Metastatic Prostate Cancer

    著者: Johann S. de Bono, Christopher J. Logothetis, Arturo Molina, Karim Fizazi, Scott North, Luis Chu, Kim N., Robert J. Jones, Oscar B. Goodman, Fred Saad, John Staffurth, Paul N. Mainwaring, Stephen Harland, Thomas W. Flaig, Thomas E. Hutson, Tina Cheng, Helen Patterson, John D. Hainsworth, Charles J. Ryan, Cora N. Sternberg, Susan Ellard, Aude Fléchon, Mansoor N. Saleh, Mark C. Scholz, Eleni Efstathiou, Andrea Zivi, Diletta Bianchini, Yohann Loriot, Nicole Chieffo, Thian Kheoh, Christopher M. Haqq, Howard I. Scher - New England Journal of Medicine 2011 被引用: 4,394

  3. Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy

    著者: Charles J. Ryan, Matthew R. Smith, Johann S. de Bono, Arturo Molina, Christopher J. Logothetis, Paul de Souza, Karim Fizazi, Paul N. Mainwaring, Josep M. Piulats, Siobhan Ng, Joan Carles, Peter F.A. Mulders, Ethan Basch, Eric J. Small, Fred Saad, Dirk Schrijvers, Hendrik Van Poppel, Som D. Mukherjee, H. Suttmann, Winald R. Gerritsen, Thomas W. Flaig, Daniel J. George, Evan Y. Yu, Eleni Efstathiou, Allan J. Pantuck, Eric Winquist, Celestia S. Higano, Mary-Ellen Taplin, Youn Park, Thian Kheoh, Thomas W. Griffin, Howard I. Scher, Dana E. Rathkopf - New England Journal of Medicine 2012 被引用: 2,795

  4. Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer

    著者: Christopher Hoimes, Thomas W. Flaig, Matthew I. Milowsky, Terence W. Friedlander, Mehmet Asım Bilen, Shilpa Gupta, Sandy Srinivas, Jaime R. Merchan, Rana R. McKay, Daniel P. Petrylak, Carolyn Sasse, Blanca Homet Moreno, Yao Yu, Anne‐Sophie Carret, Jonathan E. Rosenberg - Journal of Clinical Oncology 2022 被引用: 267

  5. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

    著者: Charles J. Ryan, Matthew R. Smith, Karim Fizazi, Fred Saad, Peter F.A. Mulders, Cora N. Sternberg, Kurt Miller, Christopher J. Logothetis, Neal D. Shore, Eric J. Small, Joan Carles, Thomas W. Flaig, Mary-Ellen Taplin, Celestia S. Higano, Paul de Souza, Johann S. de Bono, Thomas W. Griffin, Peter De Porre, Margaret K. Yu, Youn C. Park, Jinhui Li, Thian Kheoh, Vahid Naini, Arturo Molina, Dana E. Rathkopf - The Lancet Oncology 2015 被引用: 1,354

  6. NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022

    著者: Thomas W. Flaig, Philippe E. Spiess, Michael Abern, Neeraj Agarwal, Rick Bangs, Stephen A. Boorjian, Mark K. Buyyounouski, Kevin Chan, Sam S. Chang, Terence W. Friedlander, Richard E. Greenberg, Khurshid A. Guru, Harry W. Herr, Jean Hoffman‐Censits, Amar U. Kishan, Shilajit Kundu, Subodh M. Lele, Ronac Mamtani, Vitaly Margulis, Omar Y. Mian, Jeff M. Michalski, Jeffrey S. Montgomery, Lakshminarayanan Nandagopal, Lance C. Pagliaro, Mamta Parikh, Anthony Patterson, Elizabeth R. Plimack, Kamal S. Pohar, Mark A. Preston, Kyle A. Richards, Wade J. Sexton, Arlene O. Siefker‐Radtke, Matthew K. Tollefson, Jonathan D. Tward, Jonathan L. Wright, Mary A. Dwyer, Carly J. Cassara, Lisa A. Gurski - Journal of the National Comprehensive Cancer Network 2022 被引用: 302

  7. EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma

    著者: Jonathan E. Rosenberg, Srikala S. Sridhar, Jingsong Zhang, David C. Smith, Dean Ruether, Thomas W. Flaig, Joaquina Baranda, Joshua M. Lang, Elizabeth R. Plimack, Randeep Sangha, Elisabeth I. Heath, Jamie Merchan, David I. Quinn, Sandy Srinivas, Matthew I. Milowsky, Chunzhang Wu, Elaina M. Gartner, Peiying Zuo, Amal Melhem‐Bertrandt, Daniel P. Petrylak - Journal of Clinical Oncology 2020 被引用: 327

  8. Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer

    著者: Peter H. O’Donnell, Matthew I. Milowsky, Daniel P. Petrylak, Christopher Hoimes, Thomas W. Flaig, Nataliya Mar, Helen Moon, Terence W. Friedlander, Rana R. McKay, Mehmet Asım Bilen, Sandy Srinivas, Earle F. Burgess, Chethan Ramamurthy, Saby George, Daniel M. Geynisman, Sergio Bracarda, Delphine Borchiellini, Lionnel Geoffrois, J.P. Maroto Rey, Christiano Ferrario, Anne‐Sophie Carret, Yao Yu, Maria Guseva, Blanca Homet Moreno, Jonathan E. Rosenberg - Journal of Clinical Oncology 2023 被引用: 175

  9. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

    著者: Thomas Powles, Michiel S. van der Heijden, Daniel Castellano, Matthew D. Galsky, Yohann Loriot, Daniel P. Petrylak, Osamu Ogawa, Se Hoon Park, Jae‐Lyun Lee, Ugo De Giorgi, Martin Bögemann, Aristotelis Bamias, Bernhard J. Eigl, Howard Gurney, Som D. Mukherjee, Yves Fradet, Iwona Skoneczna, Marinos Tsiatas, Andrey Novikov, Cristina Suárez, André P. Fay, Ignacio Durán, Andrea Necchi, Sophie Wildsmith, Philip He, Natasha Angra, Ashok Gupta, Wendy J. Levin, Joaquim Bellmunt, Se Hoon Park, Michiel S. van der Heijden, Andrea Necchi, Daniel Castellano, Aristotelis Bamias, Jae‐Lyun Lee, Ugo De Giorgi, Martin Bögemann, Bernhard J. Eigl, Marinos Tsiatas, Thomas Powles, Andrey Novikov, Iwona Skoneczna, Som D. Mukherjee, Cristina Suárez, Hans M. Westgeest, Yves Fradet, Aude Fléchon, Yen‐Chuan Ou, Inkeun Park, Vsevolod Matveev, Begoña Pérez‐Valderrama, Susanna Cheng, Stephen Jay Frank, Howard Gurney, Urbano Anido, Alketa Hamzaj, Margitta Retz, Srikala S. Sridhar, Giorgio V. Scagliotti, Jens Voortman, B. Yа. Alekseev, Anna Alyasova, B. K. Komyakov, Herlinde Dumez, Michel Pavic, Go Kimura, Atsushi Mizokami, Susanne Osanto, José Ángel Arranz, Djura Piersma, Sang Joon Shin, O. B. Karyakin, Ignacio Delgado, José Luis González, See‐Tong Pang, Anna Tran, Oleg Lipatov, Wen-Pin Su, Thomas W. Flaig, Ajjai Alva, Hwa Park Kyong, Evgeny Kopyltsov, Elena Almagro, M. Doménech, Yen‐Hwa Chang, Brieuc Sautois, Andre Ravaux, Gerasimos Aravantinos, V. Georgoulias, Sasja F. Mulder, Yu Jung Kim, Fabio Kater, Christine Chevreau, Scott T. Tagawa, Paweł Zalewski, Florence Joly, Yohann Loriot, Gencay Hatiboglu, Luca Gianni, Franco Morelli ほか 127 名 - The Lancet Oncology 2020 被引用: 498

  10. Bladder Cancer, Version 1.2026, NCCN Clinical Practice Guidelines In Oncology

    著者: Thomas W. Flaig, Philippe E. Spiess, Neeraj Agarwal, Rick Bangs, Stephen A. Boorjian, Mark K. Buyyounouski, Sam S. Chang, Tracy M. Downs, Jason A. Efstathiou, Terence W. Friedlander, Richard E. Greenberg, Khurshid A. Guru, Thomas Guzzo, Harry W. Herr, Jean Hoffman‐Censits, Christopher Hoimes, Brant A. Inman, Masahito Jimbo, A. Karim Kader, Subodh M. Lele, Jeff M. Michalski, Jeffrey S. Montgomery, Lakshminarayanan Nandagopal, Lance C. Pagliaro, Sumanta K. Pal, Anthony Patterson, Elizabeth R. Plimack, Kamal S. Pohar, Mark A. Preston, Wade J. Sexton, Arlene O. Siefker‐Radtke, Jonathan D. Tward, Jonathan L. Wright, Lisa A. Gurski, Alyse Johnson-Chilla - Journal of the National Comprehensive Cancer Network 2020 被引用: 628

  11. Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer

    著者: James L. Gulley, Michael Borre, Nicholas J. Vogelzang, Siobhan Ng, Neeraj Agarwal, Chris Parker, David Pook, Per Rathenborg, Thomas W. Flaig, Joan Carles, Fred Saad, Neal D. Shore, Liddy Chen, Christopher R. Heery, Winald R. Gerritsen, Frank Priou, Niels Christian Langkilde, A I Novikov, Philip W. Kantoff - Journal of Clinical Oncology 2019 被引用: 278

  12. Bladder Cancer, Version 3.2024

    著者: Thomas W. Flaig, Philippe E. Spiess, Michael Abern, Neeraj Agarwal, Rick Bangs, Mark K. Buyyounouski, Kevin Chan, Sam S. Chang, Paul Chang, Terence W. Friedlander, Richard E. Greenberg, Khurshid A. Guru, Harry W. Herr, Jean Hoffman‐Censits, Hristos Z. Kaimakliotis, Amar U. Kishan, Shilajit Kundu, Subodh M. Lele, Ronac Mamtani, Omar Y. Mian, Jeff M. Michalski, Jeffrey S. Montgomery, Mamta Parikh, Anthony Patterson, Charles C. Peyton, Elizabeth R. Plimack, Mark A. Preston, Kyle A. Richards, Wade J. Sexton, Arlene O. Siefker‐Radtke, Tyler F. Stewart, Debasish Sundi, Matthew K. Tollefson, Jonathan D. Tward, Jonathan L. Wright, Carly J. Cassara, Lisa A. Gurski - Journal of the National Comprehensive Cancer Network 2024 被引用: 236

  13. Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes

    著者: Joshua J. Meeks, Hikmat Al‐Ahmadie, Bishoy M. Faltas, John A. Taylor, Thomas W. Flaig, David J. DeGraff, Emil Christensen, Benjamin L. Woolbright, David J. McConkey, Lars Dyrskjøt - Nature Reviews Urology 2020 被引用: 195

  14. A study of high‐dose oral silybin‐phytosome followed by prostatectomy in patients with localized prostate cancer

    著者: Thomas W. Flaig, Michael Glodé, Daniel L. Gustafson, Adrie van Bokhoven, Yuzhen Tao, Shandra Wilson, Lih‐Jen Su, Yuan Li, Gail S. Harrison, Rajesh Agarwal, E. David Crawford, M. Scott Lucia, Michaël Pollak - The Prostate 2010 被引用: 191

  15. A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients

    著者: Thomas W. Flaig, Daniel L. Gustafson, Lih‐Jen Su, Joseph A. Zirrolli, Frances Crighton, Gail S. Harrison, A. Scott Pierson, Rajesh Agarwal, L. Michael Glodé - Investigational New Drugs 2006 被引用: 317

  16. TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer

    著者: Samuel R. Denmeade, Hao Wang, Neeraj Agarwal, David C. Smith, Michael T. Schweizer, Mark N. Stein, Vasileios J. Assikis, Przemyslaw Twardowski, Thomas W. Flaig, Russell Z. Szmulewitz, Jeffrey M. Holzbeierlein, Ralph J. Hauke, Guru Sonpavde, Jorge A. García, Arif Hussain, Oliver Sartor, Shifeng Mao, Harry Cao, Wei Fu, Ting Wang, Rehab Abdallah, Su Jin Lim, Vanessa Bolejack, Channing J. Paller, Michael A. Carducci, Mark C. Markowski, Mario A. Eisenberger, Emmanuel S. Antonarakis - Journal of Clinical Oncology 2021 被引用: 137

  17. Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study

    著者: Fred Saad, Eleni Efstathiou, Gerhardt Attard, Thomas W. Flaig, Fábio Franke, Oscar B. Goodman, Stéphane Oudard, Thomas Steuber, Hiroyoshi Suzuki, Daphne Wu, Kesav Yeruva, Peter De Porre, Sabine Brookman‐May, Susan Li, Jinhui Li, Shibu Thomas, Katherine B. Bevans, Suneel Mundle, Sharon McCarthy, Dana E. Rathkopf - The Lancet Oncology 2021 被引用: 106

  18. A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695)

    著者: Thomas W. Flaig, Catherine M. Tangen, Siamak Daneshmand, Ajjai Alva, Seth P. Lerner, M. Scott Lucia, David J. McConkey, Dan Theodorescu, Amir Goldkorn, Matthew I. Milowsky, Rick Bangs, Gary R. MacVicar, Bruno R. Bastos, Jared S. Fowles, Daniel L. Gustafson, Melissa Plets, Ian M. Thompson - Clinical Cancer Research 2021 被引用: 91

  19. Cell-free DNA Methylation as a Predictive Biomarker of Response to Neoadjuvant Chemotherapy for Patients with Muscle-invasive Bladder Cancer in SWOG S1314

    著者: Yi‐Tsung Lu, Melissa Plets, Gareth Morrison, Alexander Cunha, Steven Cen, Suhn K. Rhie, Kimberly D. Siegmund, Siamak Daneshmand, David I. Quinn, Joshua J. Meeks, Seth P. Lerner, Daniel P. Petrylak, David J. McConkey, Thomas W. Flaig, Ian M. Thompson, Amir Goldkorn - European Urology Oncology 2023 被引用: 30

  20. Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer

    著者: Ashish M. Kamat, Thomas W. Flaig, H. Barton Grossman, Badrinath R. Konety, Donald L. Lamm, Michael A. O’Donnell, Edward Uchio, Jason A. Efstathiou, John A. Taylor - Nature Reviews Urology 2015 被引用: 246

  21. Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade

    著者: Thomas W. Flaig, Maren Salzmann‐Sullivan, Lih‐Jen Su, Zhiyong Zhang, Molishree Joshi, Miguel A. Gijón, Jihye Kim, John J. Arcaroli, Adrie van Bokhoven, M. Scott Lucia, Francisco G. La Rosa, Isabel R. Schlaepfer - Oncotarget 2017 被引用: 101

  22. Study EV-103 dose escalation/cohort A: Long-term outcome of enfortumab vedotin + pembrolizumab in first-line (1L) cisplatin-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC) with nearly 4 years of follow-up.

    著者: Shilpa Gupta, Jonathan E. Rosenberg, Rana R. McKay, Thomas W. Flaig, Daniel P. Petrylak, Christopher Hoimes, Terence W. Friedlander, Mehmet Asım Bilen, Sandy Srinivas, Earle F. Burgess, Jaime R. Merchan, Scott T. Tagawa, Jason R. Brown, Yao Yu, Anne‐Sophie Carret, Heidi S. Wirtz, Maria Guseva, Blanca Homet Moreno, Matthew I. Milowsky - Journal of Clinical Oncology 2023 被引用: 21

  23. KEYNOTE-921: Phase III Study of Pembrolizumab Plus Docetaxel for Metastatic Castration-Resistant Prostate Cancer

    著者: Daniel P. Petrylak, Raffaele Ratta, Rustem Gafanov, Gaetano Facchini, Josep M. Piulats, Gero Kramer, Thomas W. Flaig, Sreenivasa R Chandana, Ben Li, Joseph E. Burgents, Karim Fizazi - Future Oncology 2021 被引用: 49

  24. Defining “platinum-ineligible” patients with metastatic urothelial cancer (mUC).

    著者: Shilpa Gupta, Joaquim Bellmunt, Elizabeth R. Plimack, Guru Sonpavde, Petros Grivas, Andrea B. Apolo, Sumanta K. Pal, Arlene O. Siefker‐Radtke, Thomas W. Flaig, Matt D. Galsky, Jonathan E. Rosenberg, Platinum-Ineligibility in Bladder Cancer Working Group - Journal of Clinical Oncology 2022 被引用: 41